Any Xmas, New Year complacency may fuel short case surge early Jan: Experts
By
Ashish Srivastava ( IANS) |
Published on
Thu, Dec 24 2020 20:33 IST |
0 Views
New Delhi: People throng India Gate on the first day of the new year, in New Delhi on Jan 1, 2020. . Image Source: IANS News
New Delhi, Dec 24 : As the year of the pandemic seems set to conclude with a week of festivities which could kick-off from Christmas, health experts apprehend that a possible coronavirus case surge, although shorter than earlier ones, may hit the national capital in the first two weeks of 2021.
As per the experts, traits observed among the public such as a wilful ignorance to Covid-appropriate behaviour, pandemic fatigue with health directions, travel and impulse to indulge in large gatherings for celebrations likely to exacerbate the disease burden in Delhi which might lead to a short surge of the cases.
Covid-19 vaccination: Can India deliver that shot to all?
Fri, Dec 18 2020 07:37:33 PM
New Delhi, Dec 18 (IANS): As the wealthy nations like the US and the UK begin vaccinating their public, the road ahead for India does not look very rosy as both Pfizer-BioNTech and Moderna vaccines currently making headlines are yet to reach the country owing to a host of factors including scarce supply, tricky transport and an absence of proper cold chain.
For over 130 crore Indians, two promising vaccines Astrazeneca and Oxford university developed and Serum Institute of India (SII)-manufactured Covishield, and Covaxin by Bharat Biotech Ltd – are still a distant dream owing to factors not in the control of the manufacturers or the government.
Covid-19 vaccination: Can India deliver that shot to all?
Covid-19 vaccination: Can India deliver that shot to all? Saturday, December 19, 2020 IWK Bureau
As the wealthy nations like the US and the UK begin vaccinating their public, the road ahead for India does not look very rosy as both Pfizer-BioNTech and Moderna vaccines currently making headlines are yet to reach the country owing to a host of factors including scarce supply, tricky transport and an absence of proper cold chain.
For over 130 crore Indians, two promising vaccines Astrazeneca and Oxford university developed and Serum Institute of India (SII)-manufactured Covishield, and Covaxin by Bharat Biotech Ltd are still a distant dream owing to factors not in the control of the manufacturers or the government.